CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation

Qianwen Xu<sup>1</sup>, Hui Xu<sup>2</sup>, Lei Xue<sup>2</sup>, Min Wang<sup>3</sup>, Guifang Pan<sup>3</sup>, Xuhan Zhang<sup>2</sup>, Kaidi Song<sup>2</sup>, Wen Yao<sup>2</sup>, Xiang Wan<sup>2</sup>, Juan Tong<sup>2</sup>, Huilan Liu<sup>2</sup>, Hanying Xu<sup>3</sup>, Xin Liu<sup>2</sup>, Xiao-yu Zhu<sup>2</sup>, Zi-min Sun<sup>2</sup>, Lin Yang<sup>3</sup>, and Xing-bing Wang<sup>1</sup>

November 9, 2020

## Abstract

Background Few therapies are available for treating patients with B acute lymphoblastic leukemia (B-ALL) who relapse after umbilical cord blood transplant (UCBT). Chimeric antigen receptor (CAR)-modified T cell therapy targeting CD19 is novel and effective for treating refractory/relapsed (R/R) hematological malignancies. Method We report the response rate, toxicity, and survival of CD19-targeted CAR modified T cells administered to 10 patients with B-ALL who relapsed after UCBT from April 2018 to September 2019. Patients [?]14 years of age were subsequently recruited in the clinical trial (NCT02851589) conducted at the First Affiliated Hospital of USTC, Hefei, China. Results Patients (n = 11) were infused with peripheral blood T cells transduced with CD19-directed CAR lentiviral vectors (0.42 × 106 –3.91 × 106 cells/kg body weight). Among 10 patients who were successfully infused, 9 achieved minimal residual disease-negative complete remission (MRD-neg CR). As of July 30, 2020, 6 of 10 patients experienced a relapse (median follow-up for CR was 13.2 months, range 5.8–31.7 months). The 6-month rates of progression-free survival (PFS) and overall survival (OS) were 44.4% and 77.8%, respectively. Toxicities were reversible, including severe cytokine release syndrome (CRS) ([?] grade 3) and neurotoxicity in 10% (1/10) and 10% (1/10) of patients, respectively, and no patient experienced graft-versus-host disease (GVHD). Conclusion CD19-targeted CAR-modified T cell therapy may therefore serve as a safe and effective approach for treating patients with relapsed B-ALL after UCBT. A multicenter clinical trial including more subjects is required to confirm safety and efficacy.

## Hosted file

Manuscript.pdf available at https://authorea.com/users/374225/articles/491792-cd19-targeted-chimeric-antigen-receptor-modified-t-cells-induce-remission-in-patients-with-relapsed-acute-b-lymphoblastic-leukemia-after-umbilical-cord-blood-transplantation


## Hosted file


Table.pdf available at https://authorea.com/users/374225/articles/491792-cd19-targeted-chimeric-antigen-receptor-modified-t-cells-induce-remission-in-patients-with-relapsed-acute-b-lymphoblastic-leukemia-after-umbilical-cord-blood-transplantation

<sup>&</sup>lt;sup>1</sup>Anhui Medical University

<sup>&</sup>lt;sup>2</sup>The First Affiliated Hospital of USTC

<sup>&</sup>lt;sup>3</sup>PersonGen-Anke Cellular Therapeutics Co., Ltd.





Time from CAR T cell infusion (days)

